List of Excipients in Branded Drug OXYBUTYNIN CHLORIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
NCS HealthCare of KY Inc dba Vangard Labs	OXYBUTYNIN CHLORIDE	oxybutynin chloride	0615-7521	BUTYLATED HYDROXYTOLUENE
NCS HealthCare of KY Inc dba Vangard Labs	OXYBUTYNIN CHLORIDE	oxybutynin chloride	0615-7521	HYPROMELLOSES
NCS HealthCare of KY Inc dba Vangard Labs	OXYBUTYNIN CHLORIDE	oxybutynin chloride	0615-7521	LACTOSE

Generic Drugs Containing OXYBUTYNIN CHLORIDE

Company	Ingredient	NDC	Excipient
Pharmaceutical Associates Inc	oxybutynin chloride	0121-0671	CITRIC ACID MONOHYDRATE
Pharmaceutical Associates Inc	oxybutynin chloride	0121-0671	FD&C GREEN NO. 3
Pharmaceutical Associates Inc	oxybutynin chloride	0121-0671	GLYCERIN

What are the Most Frequently-Used Excipients in OXYBUTYNIN CHLORIDE?

# Of NDCs	Excipient
1	ALGINIC ACID
3	ALUMINUM HYDROXIDE
9	ALUMINUM OXIDE

Oxybutynin Chloride Excipient Strategy, Patent Status, and Commercial Opportunities

Last updated: October 21, 2026

Oxybutynin chloride is a mature antimuscarinic drug used for overactive bladder, urge urinary incontinence, and neurogenic detrusor overactivity. Its principal commercial opportunities are differentiated delivery systems, tolerability improvements, pediatric and geriatric dosage forms, transdermal products, and cost-efficient generic formulations. Composition-of-matter exclusivity has expired, and competition is primarily governed by formulation performance, regulatory strategy, manufacturing capability, and brand differentiation.

What dosage forms and excipients are used in oxybutynin chloride products?

Oxybutynin chloride is marketed in immediate-release oral tablets, oral solution, extended-release tablets, transdermal patches, and topical gel. Each dosage form requires a different excipient strategy.

Dosage form	Representative strength	Primary delivery objective	Key excipient priorities
Immediate-release tablet	5 mg	Rapid systemic delivery	Compressibility, dissolution, dose uniformity, low-cost manufacturing
Oral solution or syrup	5 mg/5 mL	Flexible dosing and swallowing convenience	Solubility, taste masking, preservative system, viscosity control
Extended-release tablet	5, 10, 15 mg	Once-daily delivery	Matrix or osmotic release control, coating integrity, robustness
Transdermal patch	Approximately 3.9 mg/day	Continuous systemic delivery	Adhesion, drug flux, skin tolerability, moisture control
Topical gel	10% oxybutynin chloride	Continuous transdermal delivery	Solubilization, evaporation rate, spreading, residual drug control

Oxybutynin chloride is a relatively potent, water-soluble salt. That supports conventional oral products but does not eliminate formulation challenges. The primary commercial liabilities are anticholinergic adverse effects, particularly dry mouth, constipation, blurred vision, urinary retention, and heat intolerance. Transdermal delivery can reduce peak plasma concentrations and may improve dry-mouth tolerability relative to oral immediate-release dosing, although treatment discontinuation remains a market constraint. (DailyMed, 2024a; DailyMed, 2024b)

What excipients are used in immediate-release oxybutynin tablets?

Immediate-release oxybutynin tablets are relatively straightforward products. A typical formula can use microcrystalline cellulose, lactose or another filler, a disintegrant, a lubricant, and a film-coating system.

Recommended immediate-release excipient platform

Functional role	Candidate excipients	Commercial rationale
Diluent	Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate	Controls tablet weight and supports direct compression
Binder	Povidone, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup
Lubricant	Magnesium stearate, sodium stearyl fumarate	Enables high-throughput compression
Glidant	Colloidal silicon dioxide	Improves powder flow
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide	Improves appearance, handling, and swallowability

Mannitol and copovidone can support a lower-density, rapidly disintegrating tablet. This is useful for orally disintegrating or chewable development, although the strong bitterness of oxybutynin chloride makes taste masking essential.

The principal generic risks are dissolution drift, content-uniformity failures at low dose, sticking during compression, and excipient-related changes in bioavailability. A direct-compression formulation is commercially attractive where the API has suitable flow and particle-size characteristics. Wet granulation may be preferable when the API or blend produces poor content uniformity.

What excipients are best for oxybutynin oral solution and pediatric products?

Oxybutynin oral solution can target pediatric patients, patients with dysphagia, and institutional-care settings. The central formulation problem is taste. Anticholinergic drugs can produce a strong, persistent bitterness that is difficult to conceal with flavor alone.

Pediatric and dysphagia formulation options

A commercial oral solution may use:

• Glycerin, sorbitol, or a combination as a sweetening and mouthfeel system.
• Sucralose, acesulfame potassium, or another high-intensity sweetener.
• Citric acid and citrate buffer for pH control.
• Hydroxyethyl cellulose or xanthan gum for viscosity.
• Potassium sorbate or sodium benzoate where compatible with the target pH.
• Fruit, berry, or citrus flavor systems selected through human taste testing.
• Chelating agents such as disodium edetate where justified by stability data.

Sugar-free formulations are preferable for chronic use and may expand use in diabetic patients. Sorbitol concentrations must be controlled because excessive exposure can cause gastrointestinal discomfort. Ethanol should generally be avoided in pediatric products unless its presence is necessary and acceptable under the applicable regulatory framework.

An oral solution can create a commercial niche even where tablet generics are commoditized. The strongest opportunities are unit-dose cups, oral syringes, preservative-free presentations, and formulations with measured-dose adapters that reduce administration errors.

What excipients are used in oxybutynin extended-release tablets?

The most technically significant oral product is the once-daily extended-release tablet. Ditropan XL used an osmotic delivery design. The commercial value of this approach lies in release control rather than in a novel active ingredient.

An extended-release oxybutynin product can use either an osmotic system or a polymeric matrix.

Osmotic system

An osmotic tablet generally includes:

• A drug layer containing oxybutynin chloride and hydrophilic excipients.
• An osmotic push layer containing a swellable polymer and osmogen.
• A semipermeable membrane, commonly based on cellulose acetate.
• A laser-drilled orifice controlling drug release.
• Pore-forming agents, plasticizers, and coating modifiers.

Hydroxyethyl cellulose, polyethylene oxide, sodium chloride, and related osmotic agents can support controlled hydration and delivery. The membrane must provide reproducible water influx across storage conditions. Small changes in coating weight, membrane permeability, or orifice geometry can materially affect release.

Hydrophilic matrix system

A lower-cost alternative uses hypromellose, hydroxypropyl cellulose, polyethylene oxide, or carbomer in a swellable matrix. The formulation must control:

• Initial burst release.
• Gel-layer formation.
• Tablet erosion.
• Food effects.
• Alcohol-induced dose dumping.
• Release consistency across pH conditions.

A matrix system has a lower manufacturing burden than an osmotic tablet but may have a narrower performance margin. A generic developer should prioritize discriminatory dissolution methods, fed and fasted bioequivalence performance, and manufacturing scale-up data.

Commercial opportunity

A differentiated extended-release product could compete on:

• Lower pill burden.
• Smaller tablet size.
• Reduced peak-related adverse effects.
• Improved release consistency.
• Lower manufacturing cost than an osmotic platform.
• Use in patients who cannot tolerate immediate-release oxybutynin.

The commercial challenge is that generic extended-release tablets already exert substantial price pressure. A new product needs a clear regulatory or clinical distinction, such as a new dosage strength, sprinkle formulation, abuse-resistant packaging, or a 505(b)(2) strategy supported by a meaningful delivery advantage.

What excipients and technologies protect oxybutynin transdermal patches?

Transdermal delivery is the most defensible excipient-driven segment because the product must solve multiple technical problems simultaneously: drug flux, adhesion, skin tolerability, reservoir stability, and dose delivery over several days.

The Oxytrol patch delivers approximately 3.9 mg of oxybutynin per day over a four-day application period. The product uses a multilayer transdermal architecture with a backing layer, drug-containing adhesive, release liner, and excipient system designed to control flux and adhesion. (DailyMed, 2024c)

Patch excipient functions

Component	Function
Acrylic or silicone adhesive	Maintains skin contact and may act as the drug matrix
Plasticizer	Adjusts flexibility, tack, and drug mobility
Permeation enhancer	Increases oxybutynin transport through the stratum corneum
Backing film	Limits drug and moisture loss
Release liner	Protects the adhesive before use
Antioxidant or stabilizer	Controls degradation where required

The central formulation tradeoff is that stronger permeation enhancement can increase skin irritation. Commercially useful approaches include:

• Lower-irritation enhancer systems.
• Improved edge adhesion during bathing and sweating.
• Smaller patch area at the same delivery rate.
• Reduced residual adhesive after removal.
• Lower application frequency.
• Hypoallergenic adhesive systems.
• Clear or discreet patch designs.
• Longer shelf life under hot and humid conditions.

Patch development is manufacturing-intensive. Coating uniformity, web handling, die cutting, pouch sealing, and in-process drug-content testing can create meaningful barriers for smaller generic manufacturers. These barriers are practical rather than composition-of-matter patent barriers.

What formulation is used in oxybutynin topical gel?

Oxybutynin topical gel products use a hydroalcoholic or aqueous-alcoholic vehicle. Gelnique 10% is an example of a topical formulation containing oxybutynin chloride with excipients such as alcohol, glycerin, hydroxypropyl cellulose, sodium hydroxide, and purified water. (DailyMed, 2024b)

The formulation must balance four requirements:

1. Adequate oxybutynin solubilization.
2. Rapid drying after application.
3. Sufficient skin permeation.
4. Low transfer to clothing, caregivers, children, or intimate contacts.

Hydroxypropyl cellulose can provide gel structure without creating an excessively occlusive film. Ethanol supports solubilization and evaporation but can increase stinging and drying. Glycerin improves humectancy and skin feel but may slow drying if used at high concentration.

Commercial opportunities include metered-dose pumps, unit-dose sachets, lower-transfer gels, alcohol-reduced systems, and formulations with improved application-site tolerability. Packaging is important because dose accuracy depends on pump calibration, actuation force, and residual product in the container.

What patents protect oxybutynin chloride products?

Oxybutynin chloride has no meaningful remaining composition-of-matter exclusivity. The main historical patent value was concentrated in controlled-release and transdermal delivery technologies.

Protection category	Historical relevance	Current commercial significance
Composition of matter	Expired	No barrier to standard generic development
Immediate-release formulation	Generally weak and largely expired	Limited differentiation
Osmotic extended-release tablet	Significant for original Ditropan XL development	Relevant mainly to historical entry analysis and formulation design
Transdermal patch	Significant for delivery, adhesive, and manufacturing architecture	Can create practical development barriers
Topical gel	Relevant to vehicle and delivery design	Potential 505(b)(2) and lifecycle opportunity
Method of use	May cover treatment populations or dosing regimens	Limited value where broad oxybutynin use is established
Manufacturing process	Can protect coating, adhesive, or scale-up methods	Relevant to freedom-to-operate analysis

FDA Orange Book listings must be reviewed by product and strength because listed patents, delisting events, pediatric exclusivity, and litigation statements can change. The absence of a current blocking patent does not eliminate freedom-to-operate issues involving unlisted process patents, trade secrets, device claims, or foreign rights. (U.S. Food and Drug Administration, 2024a)

When does oxybutynin chloride lose exclusivity?

Oxybutynin chloride lost its principal small-molecule exclusivity years ago. The original oral and extended-release products are subject to generic competition. The remaining commercial protections are product-specific and depend on formulation, delivery device, regulatory exclusivity, trademarks, and manufacturing know-how.

FDA regulatory status

Product category	FDA pathway	Competitive status
Immediate-release tablets	ANDA	Generic competition
Oral solution	ANDA or, for differentiated products, 505(b)(2)	Smaller but addressable market
Extended-release tablets	ANDA with controlled-release bioequivalence	Established generic competition
Transdermal patch	ANDA with device and adhesion requirements	More technically difficult
Topical gel	ANDA or 505(b)(2), depending on reference-product and formulation strategy	More limited competition
New delivery system	505(b)(2) or NDA	Potential lifecycle exclusivity

The most attractive regulatory opportunity is a differentiated product that qualifies for a 505(b)(2) pathway rather than another standard immediate-release tablet. Potential candidates include a new topical delivery system, an improved pediatric formulation, or a new controlled-release dosage form.

Are there Paragraph IV challenges for oxybutynin chloride?

Paragraph IV challenges are most relevant to listed formulation patents associated with extended-release, transdermal, or topical products. For a mature product such as oxybutynin chloride, standard immediate-release ANDA filings generally face lower patent risk than technically differentiated formulations.

A Paragraph IV strategy may be commercially rational when:

• A listed formulation patent remains active.
• The reference product has substantial market share.
• The generic can demonstrate non-infringement or invalidity.
• First-filer economics justify litigation.
• The formulation has a realistic path to bioequivalence.

The main risks are failure to match release performance, patch adhesion or irritation problems, device-related deficiencies, and litigation costs. An ANDA applicant should assess Orange Book-listed patents, regulatory exclusivity, patent-family continuations, and unlisted process claims before committing to a first-filer program.

Which companies compete with oxybutynin chloride products?

Competition comes from both oxybutynin manufacturers and alternative overactive-bladder therapies.

Competitive group	Examples	Commercial effect
Oxybutynin generics	Multiple ANDA holders	Price compression in oral tablets
Branded oxybutynin delivery systems	Extended-release, patch, and gel products	Retain value through convenience and tolerability
Other antimuscarinics	Tolterodine, solifenacin, darifenacin, trospium, fesoterodine	Compete on efficacy, selectivity, and adverse effects
Beta-3 agonists	Mirabegron, vibegron	Compete by avoiding anticholinergic burden
Non-drug therapies	Behavioral therapy, pelvic-floor treatment, botulinum toxin	Reduce addressable drug demand in selected patients

Oxybutynin remains relevant where low acquisition cost is decisive. Its disadvantage is cumulative anticholinergic burden, particularly in older adults. A transdermal or topical product can preserve oxybutynin use among patients who discontinue oral therapy because of dry mouth or gastrointestinal effects.

What commercial opportunities exist for oxybutynin excipient innovation?

The strongest opportunities are below.

1. Low-irritation transdermal systems

A patch or gel with reduced erythema, better adhesion, and lower transfer risk can compete on treatment persistence rather than price. Adhesive chemistry and packaging are central value drivers.

2. Pediatric oral solution

A sugar-free, alcohol-free, taste-masked product with an accurate oral syringe can address pediatric and dysphagia populations. A concentrated formulation could reduce administration volume.

3. Sprinkle or dysphagia-friendly extended-release product

A capsule containing coated multiparticulates could target patients unable to swallow tablets. The multiparticulate coating must preserve dose integrity and release performance after administration with soft food.

4. Lower-cost extended-release tablet

A hydrophilic matrix can reduce manufacturing complexity compared with an osmotic system. The main development requirement is robust release behavior across pH, food conditions, and manufacturing scale.

5. OTC-oriented topical presentation

Oxytrol established an OTC precedent for oxybutynin transdermal use in women aged 18 and older in the United States. A future product would need to compete on user instructions, packaging, adherence, and tolerability rather than on active-ingredient novelty. (U.S. Food and Drug Administration, 2013)

How strong is the oxybutynin chloride patent estate?

The patent estate is weak for the active ingredient and conventional oral dosage forms, but stronger from a practical standpoint for complex delivery systems. The most durable barriers are formulation know-how, device performance, adhesive manufacturing, bioequivalence data, and regulatory execution.

Segment	Patent strength	Development difficulty	Commercial attractiveness
Immediate-release tablet	Low	Low	Low to moderate
Oral solution	Low to moderate	Moderate due to taste and stability	Moderate
Extended-release tablet	Moderate historical strength	Moderate to high	Moderate
Transdermal patch	Moderate to high practical barrier	High	Moderate to high
Topical gel	Moderate	Moderate to high	Moderate
Pediatric or dysphagia product	Potentially moderate through formulation claims	Moderate	Niche but defensible

What generic launch risks exist for oxybutynin chloride?

Generic launch risks differ by dosage form.

• Immediate-release tablets face intense price competition and limited differentiation.
• Oral solutions face preservative, taste, microbial, and packaging risks.
• Extended-release tablets face dissolution and bioequivalence failures.
• Patches face adhesion, irritation, residual drug, and manufacturing-uniformity risks.
• Topical gels face dose-delivery, transfer, drying, and container-closure risks.
• 505(b)(2) products face clinical, labeling, and patent-expiry timing issues.

Geographic opportunities are strongest in markets where transdermal and topical products have limited generic penetration. United States opportunities are shaped by Orange Book listings and ANDA competition. European opportunities depend on national reimbursement, decentralized or centralized regulatory strategy, and substitution policies. Emerging markets may favor oral generics but can support localized oral-solution or transdermal products where pediatric and geriatric care infrastructure is expanding.

Key Takeaways

• Oxybutynin chloride composition-of-matter exclusivity has expired.
• Immediate-release tablets are low-barrier, highly commoditized products.
• Extended-release, transdermal, and topical formulations offer the strongest excipient-driven differentiation.
• The best commercial opportunities are low-irritation patches, low-transfer gels, pediatric oral solutions, and dysphagia-friendly extended-release products.
• A matrix extended-release tablet may reduce manufacturing cost but must demonstrate robust dissolution and bioequivalence.
• Transdermal products have the greatest practical manufacturing barrier because of adhesion, flux, coating, packaging, and skin-tolerability requirements.
• Orange Book review remains necessary for product-specific formulation patents and regulatory exclusivity.
• Biosimilar risk is not applicable because oxybutynin chloride is a synthetic small molecule. Competition proceeds through generic, NDA, or 505(b)(2) pathways.
• Commercial value depends more on delivery performance, tolerability, packaging, and manufacturing execution than on new chemical entity protection.

FAQs

Is oxybutynin chloride suitable for an orally disintegrating tablet?

Yes, but taste masking is the principal challenge. Mannitol, copovidone, crospovidone, and coated API particles can support an orally disintegrating formulation. Human taste testing is necessary because flavor-only masking may be inadequate.

Can a new oxybutynin patch receive 505(b)(2) approval?

Potentially. A new patch may use a 505(b)(2) strategy if it relies on FDA findings for an established oxybutynin product while introducing a different delivery system, strength, adhesion profile, or dosing interval.

Which excipient creates the greatest value in oxybutynin transdermal products?

No single excipient determines value. The adhesive and permeation-enhancer system usually has the greatest effect on delivery rate, skin irritation, wear time, and product differentiation.

Does oxybutynin chloride have biosimilar competition?

No. Oxybutynin chloride is a synthetic small molecule. Relevant competitors are generic oxybutynin products, branded formulations, other antimuscarinics, and beta-3 adrenergic agonists.

Is a pediatric oxybutynin formulation commercially defensible?

Yes, particularly a sugar-free, alcohol-free, taste-masked oral solution with an accurate dosing device. The opportunity is smaller than the adult tablet market but can be more defensible because palatability, dosing accuracy, and caregiver convenience are clinically important.

References

1. DailyMed. (2024a). Oxybutynin chloride tablet prescribing information. U.S. National Library of Medicine.

2. DailyMed. (2024b). Gelnique 10% oxybutynin chloride gel prescribing information. U.S. National Library of Medicine.

3. DailyMed. (2024c). Oxytrol oxybutynin transdermal system prescribing information. U.S. National Library of Medicine.

4. U.S. Food and Drug Administration. (2013). FDA approves first over-the-counter drug for overactive bladder. FDA.

5. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.